Computed tomography (CT)-defined sarcopenia and myosteatosis are prevalent in patients with neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT).
David L ChanStephen J ClarkeAlexander EngelConnie I DiakosNick PavlakisPaul J RoachDale L BaileyJudith BauerMerran FindlayPublished in: European journal of clinical nutrition (2021)
Body composition analysis is feasible using routinely acquired PET/CT data for patients with NEN. CT-defined sarcopenia and myosteatosis are prevalent in NEN patients, although myosteatosis is more common with increasing age. These findings were not associated with worsened overall or progression-free survival in the current study.
Keyphrases
- body composition
- computed tomography
- pet ct
- positron emission tomography
- dual energy
- free survival
- image quality
- contrast enhanced
- end stage renal disease
- newly diagnosed
- resistance training
- skeletal muscle
- magnetic resonance imaging
- ejection fraction
- chronic kidney disease
- bone mineral density
- big data
- peritoneal dialysis
- stem cells
- patient reported outcomes
- machine learning
- replacement therapy